Int. J. Environ. Res. Public Health 2009, 6 222 63. Foulds, J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int. J. Clin. Pract. 2006, 60, 571-576. 64. Eisenberg, M.J.; Filion, K.B.; Yavin, D.; Bélisle, P.; Mottillo, S.; Joseph, L.; Gervais, A.; O’Loughlin, J.; Paradis, G.; Rinfret, S.; Pilote, L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008, 179, 135-144. 65. Oncken, C.; Gonzales, D.; Nides, M.; Rennard, S.; Watsky, E.; Billing, C.B.; Anziano, R.; Reeves, K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch. Intern. Med. 2006, 166, 1571-1577. 66. Jorenby, D.E.; Hays, J.T.; Rigotti, N.A.; Azoulay, S.; Watsky, E.J.; Williams, K.E.; Billing, C.B.; Gong, J.; Reeves, K.R. Efficacy of varenicline, an α4b2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296, 56-63. 67. Gonzales, D.; Rennard, S.I.; Nides, M.; Oncken, C.; Azoulay, S.; Billing, C.B.; Watsky, E.J.; Gong, J.; Williams, K.E.; Reeves, K.R. Varenicline, an α4b2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296, 47-55. 68. Tonstad, S.; Tonnesen, P.; Hajek, P.; Williams, K.E.; Billing, C.B.; Reeves, K.R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296, 64-71. 69. Nides, M.C.O.; Gonzales, D.; Rennard, S.I.; Watsky, E.J.; Anziano, R.; Reeves, K.R. Smoking cessation with varenicline, a selective alpha-4-beta-2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion controlled trial with 1-year follow-up. Arch. Intern. Med. 2006, 166, 1561-1568. 70. Lyon, G.J. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J. Clin. Psychopharmacol. 2008, 28, 720-721. 71. Pumariega, A.J.; Nelson, R.; Rotenberg. L. Varenicline-Induced Mixed Mood and Psychotic Episode in a Patient with a Past History of Depression. CNS Spectr. 2008, 13, 511-514. 72. Food and Drug Administration. FDA Med Watch Alert, Varenicline (marketed as Chantix): Information, February 1, 2008, and November 20, 2007. Available at www.fda.gov/cder/drug/infopage/varenicline/default.htm (accessed December 10, 2008). 73. Kohen, I.; Kremen, N. Varenicline-induced manic episode in a patient with bipolar disorder. Am. J. Psychiatry 2007, 164, 1269-1270. 74. Freedman, R. Exacerbation of schizophrenia by varenicline [letter]. Am. J. Psychiatry. 2007, 164, 1269. 75. Schmelzle, J.; Rosser, W.W.; Birtwhistle, R. Update on pharmacologic and nnpharmacologic therapies for smoking cessation. Can. Fam. Physician 2008, 54, 994-999. 76. Sutherland, G. Current approaches to the management of smoking cessation. Drugs 2002, 62, 53- 61. 77. Lancaster, T.; Stead, L.F. Individual behavioral counseling for smoking cessation. Cochrane Database Syst. Rev. 2005, 18, CD001292.